The success of a cell or gene therapy depends on the collection of high-quality starting material, which in turn relies heavily on apheresis and collection professionals receiving applicable, highly-specialized training and ongoing support and protocol management for each unique product. With the rapid growth in cell therapy clinical trials, proven experience and shared knowledge of the apheresis infrastructure and cell therapy industry is essential to the development and management of high-performing collection networks.
Critical components for developing and managing expansive, high-performing collection networks
14th March 2019; 8:00 PDT, 10:00 CDT, 11:00 EDT, 15:00 GMT, 16:00 CET
Sign up today to join our forthcoming webinar with Amy Hines and Richard Smith of Be The Match BioTherapies, featuring a live Q&A session with the presenters and expert guest speakers.
Ms Hines will be joined by a stellar stakeholder panel for further discussion and to answer your questions:
- Joseph Vitale, PhD, Hitachi Chemical Advanced Therapeutics Solutions, LLC
- Sanjin Zvonic, PhD, WindMIL Therapeutics
- Richard J. Smith, Be The Match BioTherapies, United Kingdom
At the end of this webinar viewers will have a strong understanding of:
- The impact that high-quality starting material has on the manufacturing process, and ultimately, patient outcomes
- Challenges associated with cell collection, the resource burden currently impacting collection infrastructure, and how standardized collection processes can improve the collection of consistent, compliant and high-quality cell starting materials
- Proven strategies for the effective and efficient qualification and onboarding of collection sites
- Efficiencies that can be gained by leveraging partners with established relationships in the apheresis and collection environment
Joseph VitaleDirector, Account Management
Hitachi Chemical Advanced Therapeutics Solutions, LLC